US Patent

US7939518 — Method of treating post-surgical acute pain

Method of Use · Assigned to AAIPharma Inc · Expires 2029-02-24 · 3y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating post-surgical acute pain by administering between 13 to 30 mg of diclofenac potassium over at least 24 hours.

USPTO Abstract

A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-980 — diclofenac-potassium

Patent Metadata

Patent number
US7939518
Jurisdiction
US
Classification
Method of Use
Expires
2029-02-24
Drug substance claim
No
Drug product claim
No
Assignee
AAIPharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.